ABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , POEMS Syndrome/diagnosis , Stroke/etiology , Osteitis Deformans/diagnosis , Vascular Endothelial Growth Factors/analysis , Paraproteins/analysis , Diagnosis, Differential , Delayed Diagnosis/statistics & numerical dataABSTRACT
TITLE: Ictus menor en una paciente con trombocitopenia.
Subject(s)
Brain Ischemia/etiology , Purpura, Thrombotic Thrombocytopenic/complications , ADAMTS13 Protein/deficiency , Adrenal Cortex Hormones/therapeutic use , Aged , Brain Ischemia/diagnostic imaging , Combined Modality Therapy , Diagnosis, Differential , Dysarthria/etiology , Erythrocytes, Abnormal , Female , Humans , Magnetic Resonance Imaging , Neuroimaging , Paresis/etiology , Plasmapheresis , Purpura, Thrombotic Thrombocytopenic/blood , Purpura, Thrombotic Thrombocytopenic/enzymology , Purpura, Thrombotic Thrombocytopenic/therapyABSTRACT
OBJECTIVE: To analyze the results of the first two years of application of the clinical pathway for transurethral resection (TUR) of bladder tumors at La Paz University Hospital. METHODS: We developed a clinical pathway of 4 hospital stays (5 days) for TUR of the bladder that included the following: matrix-verification, treatments prescribed, verification of changes, patient information sheet and patient satisfaction questionnaire. The information for the evaluation of the results were obtained from the pathway records and data on the activities of the Urology services. To assess the results for efficiency in the use of resources, the mean duration of hospital stay of patients in the pathway were compared with that of a control group comprised of 50 randomly selected patients submitted to TUR of the bladder in 1997. RESULTS: From June 1998 to May 2000, 481 of the 494 (97.4%) treated patients entered the clinical pathway. CONCLUSIONS: In our experience, the clinical pathway for the urinary bladder is a useful instrument for developing the clinical management of this condition. It reduces the unwanted changes in patient care and hospital stay, carries a low incidence of complications and readmissions, and achieves a high degree of patient satisfaction.
Subject(s)
Critical Pathways , Urinary Bladder Neoplasms/surgery , Follow-Up Studies , Humans , Time Factors , Urethra , Urologic Surgical Procedures/methodsABSTRACT
OBJECTIVE: To analyze the results achieved with vacuum devices in the treatment of erectile dysfunction. METHODS: A telephone survey was conducted on 150 patients undergoing treatment with a vacuum device. Of these, 89 responded; 79 of which were considered valid for the study. The duration and frequency of use, side effects and degree of patient and partner satisfaction were analyzed. Mean follow-up was 59.5 months. RESULTS: There were 14 dropouts early in the course of treatment. The remaining 65 patients used the device for a mean duration of 34.6 months, 3.7 times monthly. 63.3% of the patients achieved erection in more than half of the attempts. The most frequent side effects were pain (27 patients) and ecchymosis (7 patients). Forty-eight patients discontinued treatment at 10.8 months' mean follow-up. The most common causes for discontinuing treatment were lack of efficacy, refusal of the partner and pain. CONCLUSIONS: Treatment of erectile dysfunction with the vacuum constriction device should be utilized as an alternative to intracavernosal drug-induced erection therapy when oral therapy fails or is contraindicated. A male with a stable partner and impotence arising from venous leakage or mild cavernous artery insufficiency is the ideal candidate.
